Filters








2,902 Hits in 4.3 sec

Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with "-OMIC" Data Fields and Therapeutic Response Signatures

Giulia Federici, Xi Gao, Janusz Slawek, Tomasz Arodz, Amanuel Shitaye, Julia D. Wulfkuhle, Ruggero De Maria, Lance A. Liotta, Emanuel F. Petricoin
2013 Molecular Cancer Research  
The NCI-60 cell line set is likely the most molecularly profiled set of human tumor cell lines in the world.  ...  many of the drug targets for new targeted therapeutics.  ...  Grant Support This work was partly supported by the Italian Istituto Superiore di Sanit a within the framework Italy/USA cooperation agreement between the U.S.  ... 
doi:10.1158/1541-7786.mcr-12-0690 pmid:23635402 fatcat:zhujbhfgaffvhbbpdiinr74gku

An Information-Intensive Approach to the Molecular Pharmacology of Cancer

J. N. Weinstein, T. G. Myers, P. M. O'Connor, S. H. Friend, A. J. Fornace, K. W. Kohn, T. Fojo, S. E. Bates, L. V. Rubinstein, N. L. Anderson, J. K. Buolamwini, W. W. van Osdol (+9 others)
1997 Science  
information on mechanisms of drug action and drug resistance.  ...  into potential target molecules and modulators of activity in the 60 cell lines.  ...  The NCI's Drug Information System (DIS) contains chemical connectivity tables for approximately 460,000 molecules, including the 60,000 tested to date.  ... 
doi:10.1126/science.275.5298.343 pmid:8994024 fatcat:iqxwhizq6vdahbs6mrii24pdg4

A new paradigm for cancer therapeutics development

Soo-Youl Kim
2010 BMB Reports  
We need to focus our energy and resources on novel drug candidate identification and optimization, in order to enhance the entry of early-stage drug candidates into the therapeutics pipeline.  ...  An example of such efforts has begun with the Drug Development Consortium, which was described in the KSBMB chapter.  ...  Acknowledgements This work was supported by a research grant (NCC0810181) from the National Cancer Center in Korea.  ... 
doi:10.5483/bmbrep.2010.43.6.383 pmid:20587327 fatcat:bjsxv2krunaohkrahljjplefua

A new paradigm for cancer therapeutics development

Soo-Youl Kim
2010 BMB Reports  
We need to focus our energy and resources on novel drug candidate identification and optimization, in order to enhance the entry of early-stage drug candidates into the therapeutics pipeline.  ...  An example of such efforts has begun with the Drug Development Consortium, which was described in the KSBMB chapter.  ...  Acknowledgements This work was supported by a research grant (NCC0810181) from the National Cancer Center in Korea.  ... 
doi:10.3858/bmbrep.2010.43.6.383 fatcat:cgme3qysifd4fcu2gwzv2757tu

Searching for Pharmacogenomic Markers: The Synergy between Omic and Hypothesis-Driven Research

John N. Weinstein
2001 Disease Markers  
We have entered the "omic" era in biology.  ...  Those cells (the NCI-60) have been characterized pharmacologically with respect to their sensitivity to > 70,000 chemical compounds.  ...  The NCI's Drug Information System (DIS) contains structural builds for ∼ 500, 000 molecules, including most of the > 70, 000 tested to date ( [27] and D. Zaharevitz, et al., unpublished).  ... 
doi:10.1155/2001/435746 pmid:11673654 pmcid:PMC3851640 fatcat:5e6lvlz23vaorg6zw3lnttztka

Sigma Receptors and Cancer

Ebru Aydar, Christopher P. Palmer, Mustafa B. A. Djamgoz
2004 Cancer Research  
An interesting possibility is that and/or 1 drugs could produce anticancerous effects by modulating ion channels.  ...  Whereas the precise molecular mechanism(s) of receptors and their involvement in cancer cell biology have not been elucidated, recent work has started to shed some light on these issues.  ...  (NCI-H209 and NCI-N417) cells (31) .  ... 
doi:10.1158/0008-5472.can-03-2329 pmid:15289298 fatcat:q3qpbk2do5dnbbmwna6zgweahm

A Genomic Strategy to Elucidate Modules of Oncogenic Pathway Signaling Networks

Jeffrey T. Chang, Carlos Carvalho, Seiichi Mori, Andrea H. Bild, Michael L. Gatza, Quanli Wang, Joseph E. Lucas, Anil Potti, Phillip G. Febbo, Mike West, Joseph R. Nevins
2009 Molecular Cell  
We propose that this model of pathway structure constitutes a framework to study the processes by which information propogates through cellular networks, and to elucidate the relationships of fundamental  ...  modules to cellular and clinical phenotypes.  ...  All aspects of the research were supported under the NCI Integrative Cancer Biology program via grant NIH 5-U54-CA112952-05 and by 5-RO1-CA106520-05 to JRN.  ... 
doi:10.1016/j.molcel.2009.02.030 pmid:19362539 pmcid:PMC2694616 fatcat:tbizqidrybfnhnmlceytbuhbti

Spotlight on Cancer Research

2011 Nature Cell Biology  
eld of systems biology.  ...  , which pools together information from 18 partners in 10 di erent states."  ... 
doi:10.1038/nj0354 fatcat:yt4aprdq3bhv5fs52mlcm3gsvm

Assessing therapeutic potential of molecules: molecular property diagnostic suite for tuberculosis $$(\mathbf{MPDS}^{\mathbf{TB}})$$ ( MPDS TB )

Anamika Singh Gaur, Anshu Bhardwaj, Arun Sharma, Lijo John, M Ram Vivek, Neha Tripathi, Prasad V Bharatam, Rakesh Kumar, Sridhara Janardhan, Abhaysinh Mori, Anirban Banerji, Andrew M Lynn (+38 others)
2017 Proceedings of the Indian Academy of sciences. Chemical sciences  
Milne G W and Miller J 1986 The NCI drug information development of antitubercular chemotherapy Expert system. 1. System overview J. Chem. Inf. Comput. Sci. Opin. Invest.  ...  Sci. 128 719 T I 2008 In Small Molecules to Systems Biology and 42.  ... 
doi:10.1007/s12039-017-1268-4 fatcat:ph6apcd5xjhz3i2hsa2mqdodvy

Biotechnology products in cancer therapy: a colloquium

E C Borden, E C Bradley, C H Evans, C F Fox, R S Metzgar, M S Mitchell, J N Weinstein
1988 Cancer Research  
MCAbs could provide efficient delivery systems for antitumor drugs.  ...  This dis cussion can be fostered by the FDA, NCI, and other groups by sponsoring symposia and other organized face-to-face contact of all parties, electronic mail, or telephone conference calls.  ...  Subscriptions Reprints and . pubs@aacr.org Department at To order reprints of this article or to subscribe to the journal, contact the AACR Publications Permissions Rightslink site.  ... 
pmid:3275492 fatcat:h7berro3qjf3fbxn4yt7dvwvre

Inhibition of Bacterial Virulence: Drug-Like Molecules Targeting the Salmonella enterica PhoP Response Regulator

Yat T. Tang, Rong Gao, James J. Havranek, Eduardo A. Groisman, Ann M. Stock, Garland R. Marshall
2012 Chemical Biology and Drug Design  
In the signaling scheme, the histidine kinase phosphorylates and activates the response regulator, which functions as a transcription factor to modulate gene expression.  ...  In this study, a hybrid approach coupling computational and experimental methods was applied to identify drug-like compounds to target the PhoP response regulator.  ...  Binding site was marked by using a docked ligand from the NCI Diversity library and specifying the regions within 5 of it.  ... 
doi:10.1111/j.1747-0285.2012.01362.x pmid:22339993 pmcid:PMC3445336 fatcat:27cjflzff5dibpkgkqodhoriui

Architecture of Signature miRNA Regulatory Networks in Cancer Chemoprevention

Sujit Nair, Ah-Ng Tony Kong
2015 Current Pharmacology Reports  
concurrent advent of systems network biology for "big data."  ...  In this review, we focus on the architecture of miRNA networks with emphasis on chemoresistance networks in response to chemotherapeutic drugs, chemoprevention networks modulated by dietary phytochemicals  ...  concurrent advent of systems network biology for "big data."  ... 
doi:10.1007/s40495-014-0014-6 fatcat:tggstf4cxrgalfxdajluwyuloy

Host Genetic Factors Predisposing to HIV-Associated Neurocognitive Disorder

Asha R. Kallianpur, Andrew J. Levine
2014 Current HIV/AIDS Reports  
The NIH Brain Initiative and Human Connectome Project, coupled with rapidly evolving systems biology and machine learning approaches for analyzing high-throughput genetic, transcriptomic and epigenetic  ...  The success of combination antiretroviral therapy (cART) in transforming the lives of HIV-infected individuals with access to these drugs is tempered by the increasing threat of HIV-associated neurocognitive  ...  (600 mg) of the drug.  ... 
doi:10.1007/s11904-014-0222-z pmid:24996618 pmcid:PMC4121535 fatcat:352xcrc6qjeedoovlo5pp5mgfu

Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer's disease

A. J. Ehrenberg, A. K. Nguy, P. Theofilas, S. Dunlop, C. K. Suemoto, A. T. Di Lorenzo Alho, R. P. Leite, R. Diehl Rodriguez, M. B. Mejia, U. Rüb, J. M. Farfel, R. E. de Lucena Ferretti-Rebustini (+8 others)
2017 Neuropathology and Applied Neurobiology  
Qualitative evidence identifies ht-NCI accumulating in the isodendritic core before the entorhinal cortex.  ...  Also, the number of ht-NCI+ neurons remained stable in DRN between all stages 0 and II.  ...  Acknowledgments We thank the families of the brain donors and staff of the São Paulo Autopsy service for their unconditional support.  ... 
doi:10.1111/nan.12387 pmid:28117917 pmcid:PMC5642282 fatcat:uab2pzhtofbcnhhqplxdwdg6sy

Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase

Arthur R Salomon, David W Voehringer, Leonard A Herzenberg, Chaitan Khosla
2001 Chemistry and Biology  
The K i for apoptolidin was 4^5 WM.  ...  molecules to modulate apoptotic pathways.  ...  We wish to acknowledge the NCI for the data shown in Fig. 7 .  ... 
doi:10.1016/s1074-5521(00)00057-0 pmid:11182320 fatcat:3llemhddlndfforjljer7sc3me
« Previous Showing results 1 — 15 out of 2,902 results